SLC5A2 and hydrops fetalis: A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials revealed a 13% reduction in all-cause mortality and a 25% reduction in cardiovascular death and hospitalization with SGLT2 inhibitors [22].